145 related articles for article (PubMed ID: 38491538)
1. A case report of drug interaction between co-packaged nirmatrelvir-ritonavir and tacrolimus causing hyponatremia in a lung transplant recipient.
Lo CM; Chen WH; Tsai MY; Lu HI; Hsiao YH; Chuang KH; Chen Y; Wu HF; Huang KT; Wang YH
J Cardiothorac Surg; 2024 Mar; 19(1):132. PubMed ID: 38491538
[TBL] [Abstract][Full Text] [Related]
2. The effects of nirmatrelvir/ritonavir on tacrolimus levels in lung transplant recipients: A single-center study.
Wang X; Du W; Zhang D; Chen W; Zuo X
Pulm Pharmacol Ther; 2024 Mar; 84():102280. PubMed ID: 38065402
[TBL] [Abstract][Full Text] [Related]
3. Adaptative Strategy of Immunosuppressive Drugs Dosage Adjustments When Combined With Nirmatrelvir/Ritonavir in Solid Organ Transplant Recipients With COVID-19.
Boland L; Devresse A; Monchaud C; Briol S; Belaiche S; Giguet B; Couzi L; Thaunat O; Esposito L; Meszaros M; Roussoulieres A; Haufroid V; Le Meur Y; Lemaitre F
Transpl Int; 2024; 37():12360. PubMed ID: 38596505
[TBL] [Abstract][Full Text] [Related]
4. Nirmatrelvir/ritonavir treatment in SARS-CoV-2 positive kidney transplant recipients - a case series with four patients.
Schneider J; Wobser R; Kühn W; Wagner D; Tanriver Y; Walz G
BMC Nephrol; 2023 Apr; 24(1):99. PubMed ID: 37061677
[TBL] [Abstract][Full Text] [Related]
5. Phenytoin enzyme induction for management of supratherapeutic tacrolimus levels due to drug-drug interaction with nirmatrelvir/ritonavir: Case series and discussion.
Marsh J; Logan AT; Bilgili EP; Bowman LJ; Webb AR
Am J Health Syst Pharm; 2024 Jun; 81(13):e345-e352. PubMed ID: 38347740
[TBL] [Abstract][Full Text] [Related]
6. Management of nirmatrelvir/ritonavir and tacrolimus interaction in kidney transplant recipients infected by COVID-19: a three-case series.
Guzmán Cordero C; Saez-Torres de Vicente M
Eur J Hosp Pharm; 2024 Feb; 31(2):175-177. PubMed ID: 36535689
[TBL] [Abstract][Full Text] [Related]
7. A case report of a prolonged decrease in tacrolimus clearance due to co-administration of nirmatrelvir/ritonavir in a lung transplant recipient receiving itraconazole prophylaxis.
Tsuzawa A; Katada Y; Umemura K; Sugimoto M; Nishikawa A; Sato YK; Yoshida Y; Kitada N; Yonezawa A; Nakajima D; Date H; Terada T
J Pharm Health Care Sci; 2023 Apr; 9(1):12. PubMed ID: 37004119
[TBL] [Abstract][Full Text] [Related]
8. Nirmatrelvir/ritonavir Use With Tacrolimus in Lung Transplant Recipients: A Single-center Case Series.
Dewey KW; Yen B; Lazo J; Seijo L; Jariwala R; Shah RJ; Quan D; Carpenter B; Paul Singer J; Breen K; Hays S; Florez R
Transplantation; 2023 May; 107(5):1200-1205. PubMed ID: 36525555
[TBL] [Abstract][Full Text] [Related]
9. Nirmatrelvir/ritonavir-induced elevation of blood tacrolimus levels in a patient in the maintenance phase post liver transplantation.
Shiohira H; Arakaki S; Uehara W; Uehara H; Yamamoto K; Nakamura K
J Infect Chemother; 2024 Jan; 30(1):77-80. PubMed ID: 37689137
[TBL] [Abstract][Full Text] [Related]
10. Paxlovid (Nirmatelvir/Ritonavir) and Tacrolimus Drug-Drug Interaction in a Kidney Transplant Patient with SARS-2-CoV infection: A Case Report.
Prikis M; Cameron A
Transplant Proc; 2022; 54(6):1557-1560. PubMed ID: 35599203
[TBL] [Abstract][Full Text] [Related]
11. Elevated tacrolimus levels after treatment with nirmatrelvir/ritonavir (Paxlovid) for COVID-19 infection in a child with a kidney transplant.
Young C; Papiro T; Greenberg JH
Pediatr Nephrol; 2023 Apr; 38(4):1387-1388. PubMed ID: 35982345
[TBL] [Abstract][Full Text] [Related]
12. Drug-drug interaction of Nirmatrelvir/ritonavir and tacrolimus: A potential risk disproportionality analysis of nephrotoxicity from COVID-19 reports in FAERS.
Qin F; Wang H; Li M; Zhuo S; Liu W
Expert Opin Drug Saf; 2023; 22(12):1321-1327. PubMed ID: 37477905
[TBL] [Abstract][Full Text] [Related]
13. "Saving lives with nirmatrelvir/ritonavir one transplant patient at a time".
Belden KA; Yeager S; Schulte J; Cantarin MPM; Moss S; Royer T; Coppock D
Transpl Infect Dis; 2023 Apr; 25(2):e14037. PubMed ID: 36847419
[TBL] [Abstract][Full Text] [Related]
14. Correspondence on 'Management of nirmatrelvir/ritonavir and tacrolimus interaction in kidney transplant recipients infected by COVID-19: a three-case series'.
Zhou XX; Ji HJ
Eur J Hosp Pharm; 2024 Feb; 31(2):178-179. PubMed ID: 36737228
[No Abstract] [Full Text] [Related]
15. Nirmatrelvir/ritonavir treatment of patients with COVID-19 taking tacrolimus: case series describing the results of drug-drug interactions.
Shen D; Gong Y; Qian Y; Zhu J; Gao J
J Int Med Res; 2024 May; 52(5):3000605241247705. PubMed ID: 38698526
[TBL] [Abstract][Full Text] [Related]
16. Paxlovid for treatment of COVID-19.
Med Lett Drugs Ther; 2022 Jan; 64(1642):9-10. PubMed ID: 35134040
[No Abstract] [Full Text] [Related]
17. Nirmatrelvir-ritonavir compared with other antiviral drugs for the treatment of COVID-19 patients: A systematic review and meta-analysis.
Tian F; Chen Z; Feng Q
J Med Virol; 2023 Apr; 95(4):e28732. PubMed ID: 37183808
[TBL] [Abstract][Full Text] [Related]
18. Tacrolimus toxicity due to enzyme inhibition from ritonavir.
Snee I; Drobina J; Mazer-Amirshahi M
Am J Emerg Med; 2023 Jul; 69():218.e5-218.e7. PubMed ID: 37173153
[TBL] [Abstract][Full Text] [Related]
19. Tacrolimus Drug-Drug Interaction with Nirmatrelvir/Ritonavir (Paxlovid™) Managed with Phenytoin.
Sindelar M; McCabe D; Carroll E
J Med Toxicol; 2023 Jan; 19(1):45-48. PubMed ID: 36536192
[TBL] [Abstract][Full Text] [Related]
20. Rebound of SARS-CoV-2 Infection after Nirmatrelvir-Ritonavir Treatment.
Charness ME; Gupta K; Stack G; Strymish J; Adams E; Lindy DC; Mohri H; Ho DD
N Engl J Med; 2022 Sep; 387(11):1045-1047. PubMed ID: 36069968
[No Abstract] [Full Text] [Related]
[Next] [New Search]